Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print June 4, 2008, doi:10.1212/01.wnl.0000316197.04157.6f)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
01.wnl.0000316197.04157.6fv1
71/3/202    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Silverberg, G. D.
Right arrow Articles by McGuire, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silverberg, G. D.
Right arrow Articles by McGuire, D.
Received June 5, 2007
Accepted March 19, 2008

Continuous CSF drainage in AD. Results of a double-blind, randomized, placebo-controlled study

G. D. Silverberg MD*, M. Mayo PharmD, T. Saul , J. Fellmann PhD, J. Carvalho PhD, and D. McGuire MD

From the Warren Alpert School of Medicine (G.D.S.), Brown University, Providence, RI; Affymax Inc. (M.M.), Palo Alto, CA; Saul Consulting (T.S.), Half-Moon Bay, CA; Acologix Inc. (J.F.), Hayward, CA; Genitope Inc. (J.C.), Fremont, CA; and California-Pacific Medical Center (D.M.), San Francisco.


* To whom correspondence should be addressed. E-mail: geralds{at}stanford.edu.

Background: Alzheimer disease (AD) has been associated with abnormal cerebral clearance of macromolecules, such as amyloid and microtubule-associated-protein tau (MAP-{tau}). We hypothesized that improving clearance of macromolecules from the CNS might slow the progression of dementia.

Objective: This prospective, randomized, double-blinded, placebo-controlled trial evaluated the safety and effectiveness of a surgically implanted shunt in subjects with probable AD.

Methods: A total of 215 subjects with probable AD by National Institute of Neurological Disorders and Stroke–Alzheimer's Disease and Related Disorders Association criteria received either a low-flow ventriculoperitoneal shunt or a sham (occluded) shunt for 9 months. Longitudinal CSF sampling was performed in both active and control subjects. Primary outcome measures were the Mattis Dementia Rating Scale and the Global Deterioration Scale. CSF A{beta}(1-42) and MAP-{tau} also were assayed.

Results: After a planned interim analysis, the study was halted for futility. Using the intent-to-treat population, no between-group differences were observed in the primary outcome measures. The surgical procedure and device were associated with 12 CNS infections, some temporally associated with CSF sampling. All were treated successfully.

Conclusions: We found no benefit to low-flow CSF shunting in subjects with mild to severe Alzheimer disease. CSF infections, while treatable, occurred more frequently than expected, in some cases likely related to CSF sampling.




This article has been cited by other articles:


Home page
 Br J OphthalmolHome page
P Wostyn, K Audenaert, and P P De Deyn
Alzheimer's disease and glaucoma: Is there a causal relationship?
Br J Ophthalmol, December 1, 2009; 93(12): 1557 - 1559.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by AAN Enterprises, Inc.